Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
0.7113
-0.0371 (-4.96%)
At close: Nov 20, 2026, 4:00 PM EST
0.7300
+0.0187 (2.63%)
After-hours: Nov 20, 2026, 7:53 PM EST
Annovis Bio Employees
Annovis Bio had 7 employees as of December 31, 2025. The number of employees decreased by 8 or 53.33% compared to the previous year. That makes Annovis Bio the 40,880th largest employer in the world and 6,216th in the United States.
Employees
7
Change (1Y)
-8
Growth (1Y)
-53.33%
Revenue / Employee
n/a
Profits / Employee
-$7,389,106
Market Cap
44.12M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 7 | -8 | -53.33% | 7 | 0 |
| Dec 31, 2024 | 15 | -1 | -6.25% | 8 | 7 |
| Dec 31, 2023 | 16 | 11 | 220.00% | 6 | 10 |
| Dec 31, 2022 | 5 | 2 | 66.67% | 5 | 0 |
| Dec 31, 2021 | 3 | 1 | 50.00% | 3 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Tonix Pharmaceuticals Holding | 142 |
| Mereo BioPharma Group | 39 |
| Corbus Pharmaceuticals Holdings | 36 |
| Biomea Fusion | 34 |
| Oncolytics Biotech | 29 |
| Spero Therapeutics | 25 |
| Gain Therapeutics | 21 |
| ImageneBio | 18 |
ANVS News
- 1 day ago - Annovis Bio secures FDA agreement on ISS plan for buntanetap NDA - TheFly
- 2 days ago - Annovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer's and Parkinson's Data Ahead of Buntanetap NDA - GlobeNewsWire
- 4 days ago - Annovis Bio receives second DSMB recommendation for DUET-AD trial - TheFly
- 5 days ago - Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study - GlobeNewsWire
- 5 days ago - Annovis Bio price target lowered to $3 from $7 at Roth Capital - TheFly
- 6 days ago - Annovis Bio price target lowered to $3 from $7 at Roth Capital - TheFly
- 9 days ago - Annovis Bio reports Q3 EPS (22c), consensus (33c) - TheFly
- 9 days ago - Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results - GlobeNewsWire